Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as osimertinib and gefitinib, have only been proven to be beneficial for patients with EGFR-sensitizing genetic alterations in lung cancer [23]. The gene discussed is EGFR; the disease is lung cancer.